© 2025 HSP News Service, L.L.C.
Distinguished Service Awards were presented to Kwun Fong, MBBS, PhD, FRACP; Claudia Henschke, MD, PhD; Erik Thunnissen, MD, PhD; and Julie Brahmer, MD, MSc, FASCO, during the 2024 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Adi F. Gazdar IASLC...
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
As reported in The Lancet by Spicer et al, overall survival results of the phase III KEYNOTE-671 trial indicate benefit of the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab in patients with early-stage non–small cell lung cancer (NSCLC). At the first...
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Advancing surgical and pathologic techniques may improve overall survival rates in high-risk patients with lung cancer, according to new findings presented by Akinbobola et al at the 2024 ASCO Quality Care Symposium (Abstract 278). Background “Over the past 15 years, a quality improvement...
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
As reported in the Journal of Clinical Oncology by Ahn et al, the phase III TROPION-Lung01 trial showed significantly improved progression-free survival—but not overall survival—with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with...
On September 25, the U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable (stage III) non–small cell lung cancer (NSCLC) whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiation therapy. These ...
As reported in the Journal of Clinical Oncology by Dowlati et al, extended follow-up of the phase I DeLLphi-300 trial has shown sustained benefit with tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3, in patients with previously treated small cell lung cancer....
On September 19, the U.S. Food and Drug Administration (FDA) approved amivantamab-vmjw (Rybrevant) with carboplatin and pemetrexed for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R...
The second planned interim analysis of the global phase III AEGEAN trial—reported by John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer...
Updated data from the global, multicenter, single-arm phase II TRUST-II trial, which were reported by Liu et al during the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract MA06.03), continued to demonstrate robust overall and...
Researchers have demonstrated that the combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response rates in patients with resectable non–small cell lung cancer (NSCLC), according to findings presented by Cascone et al...
Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes in patients with advanced or metastatic non–small cell lung cancer (NSCLC) treated with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan,...
The PanCan nodule management protocol may be superior at triaging lung cancer screening participants compared with the LungRADSv1.1 approach, according to new findings presented by McWilliams et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung...
Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence or mortality in patients with resectable non–small cell lung cancer (NSCLC) compared with neoadjuvant nivolumab plus chemotherapy alone, according to new...
Despite significant improvements in the perception of biomarker testing compared with a 2018 survey, substantial barriers to implementation may persist globally, according to new findings presented by Smeltzer et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World...
Researchers may have uncovered a metabolic pathway that could lead to the development of predictive biomarkers for immune checkpoint inhibitors, according to new findings presented by Kulasinghe et al at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on...
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study. The findings were presented at the International Association for...
As reported in the Journal of Clinical Oncology by Yang et al, the phase III KEYNOTE-789 trial has shown no significant improvement in progression-free or overall survival with the addition of pembrolizumab to pemetrexed/platinum in EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant...
Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...
Investigators have revealed that patients with certain chronic conditions may face delays in being diagnosed with lung cancer, according to a recent study published by Rogers et al in the British Journal of Cancer. Background Lung cancer is currently one of the leading causes of cancer-related...
As reported in The Lancet Oncology by Zhao et al, meta-analyses of trials of immune checkpoint inhibitors (ICIs) in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitor (TKI) treatment indicate that the optimal treatment strategy is...
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
Artificial intelligence (AI) tools may be used to better understand the risk of specific cardiac arrhythmias when various parts of the heart are exposed to different thresholds of radiation as part of a treatment plan for non–small cell lung cancer (NSCLC), according to a recent study published by...
The U.S. Food and Drug Administration (FDA) has approved the EGFR inhibitor lazertinib (Lazcluze) in combination with the EGFR/MET-targeting bispecific antibody amivantamab-vmjw (Rybrevant) for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer...
Researchers have developed an alternative set of simple criteria using a prediction model to identify groups of patients who may benefit most from lung cancer screening but are disproportionately excluded by current eligibility criteria, according to a new study published by Kearney et al in the...
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
The U.S. Food and Drug Administration (FDA) has approved the PD-L1 inhibitor durvalumab (Imfinzi) with platinum-containing chemotherapy as neoadjuvant treatment followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive)...
Immune checkpoint inhibitors, including atezolizumab, have been evaluated in several phase II trials for neoadjuvant therapy in resectable lung cancer, both with and without chemotherapy, such as the LCMC3 trial and CheckMate 816. Ongoing studies, including the IMpower030 trial, are further...
In an analysis from the CALGB 140503 trial reported in JAMA Oncology, Nasser Altorki, MD, and colleagues found that pathologically identified visceral pleural invasion was associated with poorer outcomes in patients undergoing surgery for non–small cell lung cancer (NSCLC). Study Details The trial ...
In a retrospective study (TURBO-NSCLC) reported in the Journal of Clinical Oncology, Pike et al found that the addition of upfront stereotactic radiosurgery (SRS) to central nervous system (CNS)-penetrant tyrosine kinase inhibitor (TKI) treatment prolonged time to CNS progression vs TKI treatment...
In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...
Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...
The survival rates of patients with advanced non–small cell lung cancer (NSCLC) have improved since the introduction of the first immunotherapeutic in this population in the United States in 2015, according to a recent study published by Wang et al in Cancer. NSCLC accounts for up to 90% of all...
Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung cancer (NSCLC), and between 1% and 2% of patients are diagnosed with RET-altered NSCLC. The results...
Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose computed tomography (CT) screening an essential component in the fight against lung cancer. Recent studies, particularly from...
In the phase II INSIGHT 2 trial reported in The Lancet Oncology, Yi-Long Wu, MD, and colleagues found that the combination of tepotinib plus osimertinib showed clinically meaningful activity in patients with advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with MET...
People who use e-cigarettes in conjunction with cigarette smoking are four times more likely to develop lung cancer than people who just smoke cigarettes, according to new study published by Harris et al the Journal of Oncology Research and Therapy. These findings were consistent across gender and...
In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...
The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...
The international meeting in Madrid of the newly formed Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) was held in May 2024. This diverse forum included health-care professionals, public health leaders, industry representatives, and patient...
This is Part 3 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the second-line treatment of ALK-positive non–small cell lung cancer (NSCLC) with CNS progression on first-line crizotinib. The patient was initially diagnosed with metastatic EML4::ALK-positive NSCLC at age 40 years in 2013. He did not have any CNS lesions present at the time of diagnosis and started treatment with first-line crizotinib. In February 2014, he developed seizures and was found to have multiple CNS lesions, which were treated with whole-brain irradiation. He subsequently enrolled in the phase I lorlatinib trial in April 2014. In November 2018, while at the 75-mg daily dose, he developed grand mal seizures with no evidence of disease progression, and lorlatinib was held; 11 days later, he returned to his baseline. He resumed treatment with lorlatinib at 50 mg daily and has maintained a near–complete response since that time. In April 2024, he developed recurrent seizures and has been holding lorlatinib since that time with resolution of symptoms. In the conversation that follows, the faculty discuss the long-term toxicities vs benefit of lorlatinib, the management of toxicities associated with lorlatinib, and the impact of dose reduction on efficacy.
This is Part 2 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the first-line management of ALK-positive non–small cell lung cancer (NSCLC) with CNS metastases at basement and CNS toxicity early in treatment. The patient is a 76-year-old prior smoker who presented to the emergency room in February 2024 with complaints of dyspnea. Imaging revealed a 3.2-cm right lower lobe lung mass and a widely metastatic process. Lung biopsy confirmed metastatic NSCLC, and liquid next-generation sequencing (NGS) revealed an EML::ALK variant 3a/b rearrangement. MRI of the brain revealed a 4-mm right frontal lobe metastasis. The patient started first-line lorlatinib at 100 mg daily in March 2024, and 3.5 weeks later showed decreased conspicuity of the CNS lesion. However, he also began to note mild confusion and “chemo fog” after his second cycle of therapy. In the conversation that follows, the faculty discuss common toxicities associated with lorlatinib, the role of dose reduction in managing toxicities, and the importance of taking a social history to obtain a holistic understanding of patients.
This is Part 1 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the first-line management of metastatic non–small cell lung cancer (NSCLC) with CNS metastases at baseline. The patient presented at age 38 years for evaluation of headaches in 2021. A head CT revealed two lesions with surrounding edema but no midline shift, which was concerning for metastatic disease. A CT of the chest, abdomen, and pelvis revealed a 4-cm left upper lobe lung mass, hilar adenopathy, and a 2-cm liver lesion. Liver biopsy confirmed metastatic NSCLC. While awaiting next-generation sequencing (NGS), the patient was started on carboplatin plus pemetrexed and was referred for radiation to the CNS lesions. NGS returned with an EML4::ALK variant 1 translocation, and she began treatment with alectinib. One week after alectinib was started, she underwent stereotactic radiosurgery to the CNS lesion. In the conversation that follows, the faculty discuss the importance of NGS testing for actionable driver mutations regardless of smoking history, appropriate therapy options when starting treatment prior to having NGS results, and the role of stereotactic radiosurgery in the first-line setting.
As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...